Publication | Closed Access

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

Hematological MalignancyLymphoid NeoplasiaFirst-line TherapyOncologyImmunologyHematologyLenalidomide MaintenanceAdult T-cell Leukemia-lymphomaMedicineCancer ResearchFinal Results